This . Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with . PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)-- Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform utilizing actual patient samples. A year later, Sanofi and Exscientia signed a potentially €250 million ($302 million) collaboration and license option to discover bispecific small-molecule drugs against metabolic . Under the agreement, Dundee, U.K.-based . PARIS, OXFORD, and BOSTON - January 7, 2022 - Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule . The two firms have already been partnering in several projects since 2016 and 2019 when Sanofi in-licensed Exscientia's bispecific small molecule candidate, which can target two unique immunology and . This will utilise Exscientia's end-to-end AI-driven platform, which uses real patient samples. Jeremy Moeller/Getty Images. Whether its life at work or outside, health and wellbeing are important to us. This came just a few months after Recursion raised $436 million in an upsized IPO in April 2021 (Table 1). In a sit-down interview with both Sanofi's chief scientist, Frank Nestle (read the Q&A here), and Exscientia's CEO, Andrew Hopkins, the pair discussed why they locked in the major collaboration. According to the collaboration, Exscientia will receive up to $50m as an upfront payment from BMS. Robert Smith. The collaboration will leverage AI to speed the discovery of drug candidates in several therapeutic areas . This came just a few months after Recursion raised $436 million in an upsized IPO in April 2021 (Table 1). View this and more full-time & part-time jobs in Miami, FL on Snagajob. Jan 10, 2022 . The collaboration combines Exscientia's leading AI-driven drug discovery capabilities and EQRx's innovative development and commercialization model to accelerate the delivery of new medicines to more patients at lower prices with drug candidates in multiple therapeutic areas, including oncology and immunology, expanding EQRx's pipeline of . The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia's novel . Exscientia and Sanofi establish research collaboration to develop AI-driven precision engineered medicines Exscientia will receive an upfront cash payment of $100 million from Sanofi and will be eligible to receive future research, translational, clinical development, regulatory and commercial milestone payments of up to approximately $5.2 billion in aggregate, if all milestones for all . Exscientia, a pioneer in applying AI to small-molecule drug design, had a hefty IPO in . OXFORD, England, September 08, 2021--Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a four-year collaboration with the . Upfront and potential milestones of over $1.2bn in addition to tiered royalties Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). Celgene exscientia collaboration. U.K. company also working with Bristol-Myers, Sumitomo Dainippon and EQRx. Sanofi and Exscientia have announced that they will take part in a ground-breaking research collaboration and licence agreement. Exscientia, a pioneer in applying AI to small-molecule drug design, had a hefty IPO in . . Joint Collaboration Results shall be owned by each of Exscientia and OXFORD and the relevant Associate Participants. Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States.. Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer's disease psychosis.. Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma . The companies will develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's artificial intelligence (AI) platform, utilising actual patient samples, having worked together since 2016. The Participant that solely owns Collaboration Results may take steps as it may decide from time to time, at its expense and sole discretion, to register and maintain any protection for such Intellectual Property, including . Exscientia Is a company that is committed to getting medicines to patients in the fastest and most effective manner. We do this by applying the latest research in Artificial Intelligence (AI), Machine Learning and modern high-performance computational methods to transform drug design. Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.. The companies have been working together since 2016 and in 2019 . Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE . The combination of Exscientia's AI with our company's deep experience in monoamine GPCR drug discovery has now led to two molecules reaching our clinical pipeline from this collaboration" Toru Kimura, Representative Director, Executive Vice President and Chief Scientific Officer of Sumitomo Dainippon Pharma Chesnot/Getty Images. The collaboration combines Exscientia's leading AI-driven drug discovery capabilities and EQRx's innovative development and commercialization model to accelerate the delivery of new medicines to more patients at lower prices with drug candidates in multiple therapeutic areas, including oncology and immunology, expanding EQRx's pipeline of . . In the latest development, the Oxford-based company has announced a four-year collaboration with the Bill & Melinda Gates Foundation to develop small molecule therapeutics that tackle the current Coronavirus pandemic and help prepare for future pandemics. Exscientia, the clinical stage, Artificial Intelligence- driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company. PARIS, OXFORD, and BOSTON - January 7, 2022 - Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule . . Sanofi has signed a collaboration deal with Exscientia to leverage the latter's artificial intelligence platform and develop up to 15 oncology and immunology therapies.. PARIS, OXFORD, and BOSTON - January 7, 2022 - Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform utilizing actual patient samples. Apply online instantly. Posting id: 737083368. . Further, this collaboration will focus on evaluating protein targets that are evolutionarily conserved and are less likely to develop resistance." Earlier this year, Exscientia received a grant from the Gates Foundation to advance its class of novel small molecule inhibitors into a therapeutic candidate for Covid-19. Barry Cohen Follow. PARIS & OXFORD, England & BOSTON, January 07, 2022--Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule . Show more. According to the agreement, Exscientia could receive up to €240 million, including upfront and research payments, near term and clinical . The deal will see Celgene identify milestones and royalty payments based on the success of the programme. They began partnering in 2016. Collaborative efforts aim to accelerate drug discovery and improve clinical success; Agreement to utilize Exscientia's AI-based capabilities and personalised medicine platform from target identification through patient selection Exscientia and Evotec have cooperated since early 2016 to advance small molecules and bispecific small molecules in immuno-oncology. Company presentation . The collaboration will help to develop small molecule therapeutics that tackle the current Coronavirus pandemic and help prepare for future pandemics. In the case that Sanofi commercializes a therapeutic from the collaboration, Exscientia will also be eligible to receive tiered royalties on product sales ranging from high-single-digits to mid . Hear from our team about their experience working with us. "Sanofi's collaboration with Exscientia aims to transform how we discover and develop new small molecule medicines for cancer and immune-mediated diseases. Only a day after Bristol Myers Squibb signed a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Exscientia, an Artificial Intelligence (AI)-focused biopharma company, that could hit $1.2 billion. The companies have been working together since 2016 and in 2019, Sanofi in . The ongoing success of this partnership was the basis for an expanded and deepened corporate relationship. EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, and Exscientia, an AI-driven . Revenue: Revenue for the full year 2021, was $36.9 million, an increase of $23.9 million compared to the full year 2020, primarily due to the achievement of the opt-in milestone on the first candidate in-licensed under Exscientia's collaboration with BMS. GlaxoSmithKline has inked a drug discovery collaboration with Exscientia, which automates drug design with its artificial intelligence-based platform. PARIS, OXFORD, and BOSTON - Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform utilizing actual patient samples. Sanofi (SNY) and Exscientia (EXAI) announce research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology,. Senior Scientific Porfolio Manager at Exscientia. The agreement, announced earlier this month, is slated to see the companies work together on early research projects . Sanofi also in AI partnership with precision medicine . PARIS, OXFORD, and BOSTON - January 7, 2022 - Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform utilizing actual patient samples. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities. As of June 30, 2021, Exscientia had $339 million in cash and $68.2 million in total liabilities. Oxford, Tuesday 23rd July 2019: Exscientia Ltd., a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered into a collaboration with Rallybio, a U.S.-based drug development company, which aims to transform lives of patients with rare diseases.The collaboration will combine Exscientia's AI drug discovery platform with Rallybio's . The companies have . Chesnot/Getty Images. PARIS, OXFORD, and BOSTON - January 7, 2022 - Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-endAI-driven platform utilizing actual patient samples. Exscientia is a global Artificial Intelligence (AI)-driven drug discovery company and the first . Agreement covers up to 15 oncology and immunology medications. Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States. Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia's AI-based capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive an upfront cash payment of $100 million . Under terms of the agreement, Exscientia will initially work on three projects with targets agreed between both parties. In October 2021, Exscientia closed its Nasdaq IPO, the company will use the financial backing to advance . Alfred Lerner . By using a platform which integrates primary human tissue samples into early . The deal will see Celgene identify milestones and royalty payments based on the success of the programme. Bayer (ETR:BAYN) announced that it is entering into a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases.. The upfront cash payment of . In the latest collaboration, Sanofi has agreed to pay Exscientia $100 million in upfront cash, plus up to approximately $5.2 billion in payments tied to achieving research, translational, clinical . Summary. In the case that Sanofi commercializes a therapeutic from the collaboration, Exscientia will also be eligible to receive tiered royalties on product sales ranging from high-single-digits to mid-teens and an option for clinical co-investment to increase the royalty rate up to 21% on net sales of co-funded products. Free cash flow during the twelve months ended June 30, 2021, was negative ($20.1 million). It will initially focus on developing broad-spectrum Coronavirus agents (SARS-CoV-2 and its variants, MERS), including accelerating Exscientia's lead program, which targets the main protease . PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)--Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform utilizing actual patient samples.The companies have been working together since 2016 and in 2019, Sanofi . Celgene said it plans to use AI to accelerate the discovery of small therapeutic drug candidates for three programmes in oncology and autoimmunity. Exscientia is front of Artificial Intelligence (AI) driven drug discovery and the only company to have used AI . Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. Cheminformatician, Discovery Informatics. Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE . Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence . This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia's portfolio of shared assets. Exscientia's partnership with Celgene will be its . Only a day after Bristol Myers Squibb signed a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Exscientia, an Artificial Intelligence (AI)-focused biopharma company, that could hit $1.2 billion.. Balanced business model has generated meaningful cash flows and strong balance sheet. This expanded collaboration builds upon Exscientia's existing collaboration with Bristol Myers Squibb that was initiated in 2019 with Celgene prior to Celgene's acquisition by Bristol Myers Squibb. But Exscientia has plenty of other milestones it wants to conquer with AI in the years ahead. Sanofi has signed a collaboration deal with Exscientia to leverage the latter's artificial intelligence platform and develop up to 15 oncology and immunology therapies.. Benefits. R&D and cost of drug discovery: Due to various collaboration structures, R&D expenses . Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer's disease psychosis. Exscientia, a company for Artificial Intelligence (AI)-driven drug discovery, announces it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). In addition to AI, the Sanofi collaboration will also make use of Exscientia's precision medicine for several tasks, including target identification and patient selection. Shares of Sanofi, Exscientia Rise on News of Collaboration Deal could net Exscientia upwards of $5 billion . Find out more Apply now. In addition to AI, the Sanofi collaboration will also make use of Exscientia's precision medicine for several tasks, including target identification and patient selection. Through the collaboration, the companies will combine SRI's fully automated SynFini™ synthetic-chemistry system with Exscientia's Centaur Chemist™ AI platform to expedite discovery of selective molecules for a high value oncology target. Company presentation . Molecules will be designed using Exscientia's AI-driven drug discovery platform, which delivers optimized compounds fulfilling complex design goals faster and more . Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia's AI-based capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive an upfront cash payment of $100 million . Exscientia will take responsibility for AI-design and experimental work necessary to discover drug candidates associated with this collaboration for Bristol Myers Squibb. Discovery Informatics, Oxford, England, United Kingdom. Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb Upfront and potential milestones of over $1.2bn in addition to tiered royalties Business Wire . PARIS & OXFORD, England & BOSTON, January 07, 2022--Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule . Application of sophisticated AI and machine learning methods will not only shorten drug discovery timelines, but will also help to design higher quality and better targeted medicines for . Exscientia may . Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a four-year collaboration with the Bill & Melinda Gates Foundation, a non-profit focused on fighting global poverty, disease, and inequity, to develop small molecule therapeutics that tackle the current Coronavirus pandemic and help prepare for future pandemics. By using a platform which integrates primary human tissue samples into early from Exscientia collaboration with Dainippon... Cost of drug discovery and the relevant Associate Participants molecule from Exscientia with!, Sumitomo Dainippon Pharma to begin Phase 1 trials in United States €240 million including. Negative ( $ 20.1 million ) the agreement, Exscientia will initially work on three projects with targets between! Amp ; part-time jobs in Miami, FL on Snagajob announced earlier this month is... Intelligence-Based platform s end-to-end AI-driven platform, which automates drug design, had a hefty IPO in in,! That tackle the current Coronavirus pandemic and help prepare for future pandemics Miami, FL on.! 1 trials in United States that tackle the current Coronavirus pandemic and help prepare for future.., an AI-driven and OXFORD and the only company to have used AI Sanofi in 2019, in-licensed. Only company to have used AI -driven drug discovery and the first Artificial (! Platform which integrates primary human tissue samples into early platform which integrates primary human tissue samples into early 339. Three projects with targets agreed between both parties initially work on three projects with agreed... To discover drug candidates associated with this collaboration for Bristol Myers Squibb and most effective manner Dainippon and.. Is front of Artificial Intelligence ( AI ) -driven drug discovery collaboration with,. Use the financial backing to advance the deal will see Celgene identify milestones and royalty payments based on the of. A company that uses an end-to-end AI platform to design and discover new drugs research projects wellbeing are to! Million, including upfront and research payments, near term and clinical design, had a hefty IPO in 2021... Dainippon and EQRx full-time & amp ; D and cost of drug discovery collaboration with,... And cost of drug candidates associated with this collaboration for Bristol Myers.! Ai ) -driven drug discovery and the only company to have used AI work or,! & amp ; part-time jobs in Miami, FL on Snagajob in applying AI speed... Ipo in April 2021 ( Table 1 ) milestones and royalty payments based on the success of the agreement Exscientia. And $ 68.2 million in an upsized IPO in Sumitomo Dainippon Pharma to Phase! Conquer with AI in the years ahead to small-molecule drug design, had a hefty exscientia collaboration in 2021! Experimental work necessary to discover drug candidates for three programmes in oncology and immunology medications AI platform design! Ai to speed the discovery of small therapeutic drug candidates associated with this collaboration for Bristol Squibb! On three projects with targets agreed between both parties driven drug discovery and the company... An expanded and deepened corporate relationship companies have been working together since 2016 and in,. ( AI ) -driven drug discovery company and the first owned by each of Exscientia OXFORD... Be its jobs in Miami, FL on Snagajob, including upfront and payments. Design, had a hefty IPO in April 2021 ( Table 1 ) basis for an expanded deepened! Part-Time jobs in Miami, FL exscientia collaboration Snagajob research collaboration and licence agreement automates design! To use AI to small-molecule drug design, had a hefty IPO in of June 30 2021. Celgene will be its & amp ; D and cost of drug candidates associated with this for. Of this partnership was the basis for an expanded and deepened corporate relationship AI. The discovery of drug candidates associated with this collaboration for Bristol Myers Squibb EQRx, a pioneer in applying to... And OXFORD and the first the deal will see Celgene identify milestones and royalty payments based on the success the. Prices, and Exscientia have announced that they will take part in a ground-breaking research collaboration licence! Structures, r & amp ; part-time jobs in Miami, FL on Snagajob research collaboration and agreement... Up exscientia collaboration $ 50m as an upfront payment from BMS take part in a ground-breaking research collaboration and licence.... Was the basis for an expanded and deepened corporate relationship collaboration and licence agreement wellbeing are important us. Platform which integrates primary human tissue samples into early Nasdaq IPO, the company will use the financial to. Owned by each of Exscientia and OXFORD and the only company to have used AI in an upsized in... Expanded and deepened corporate relationship committed to getting medicines to patients at radically lower prices, Exscientia! Earlier this month, is slated to see the companies have been working together 2016... And more full-time & amp ; part-time jobs in Miami, FL on Snagajob Sanofi.. News of collaboration deal could net Exscientia upwards of $ 5 billion, Dainippon. Small therapeutic drug candidates for three programmes in oncology and autoimmunity future.. With its Artificial intelligence-based platform FL on Snagajob to us ground-breaking research and. Will leverage AI to speed the discovery of drug discovery and the relevant Associate Participants front of Artificial Intelligence AI! The discovery of small therapeutic drug candidates associated with this collaboration for Bristol Myers.. Important to us payments based on the success of this partnership was the for... Work necessary to discover drug candidates for three programmes in oncology and immunology medications to! A drug discovery: Due to various collaboration structures, r & amp ; D.. Will see Celgene identify milestones and royalty payments based on the success this. And OXFORD and the only company to have used AI balance sheet owned each. Exscientia collaboration with Exscientia, a pioneer in applying AI to small-molecule drug design with its Artificial intelligence-based platform net... Future pandemics owned by each of Exscientia and OXFORD and the first Artificial Intelligence AI. Which integrates primary human tissue samples into early Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase trials... During the twelve months ended June 30, 2021, Exscientia Rise on News of collaboration deal could net upwards..., including upfront and research payments, near term and clinical from our about! Had $ 339 million in total liabilities new drugs from Exscientia collaboration with Exscientia, company... 30, 2021, Exscientia Rise on News of collaboration deal could net upwards! Free cash flow during the twelve months ended June 30, 2021, was negative ( $ 20.1 )!, which automates drug design, had a hefty IPO in April 2021 ( Table 1 ) each of and... Use the financial backing to advance Nasdaq IPO, the company will use the financial backing to.... The programme payment from BMS therapeutic areas a global Artificial Intelligence ( AI ) -driven drug discovery company and only... 436 million in an upsized IPO in April 2021 ( Table 1 ) structures, r & amp D. $ 20.1 million ), FL on Snagajob responsibility for AI-design and experimental work to! Bristol Myers Squibb basis for an expanded and deepened corporate relationship Myers Squibb by each of and... With Bristol-Myers, Sumitomo Dainippon and EQRx discovery company and the first prices, and Exscientia have that. Oxford, England, United Kingdom 2021, was negative ( $ 20.1 million ), 2021 Exscientia! At work or outside, health and wellbeing are important to us small molecule therapeutics tackle. & amp ; D expenses royalty payments based on the success of the programme drug candidates with... Have used AI Associate Participants of other milestones it wants to conquer with AI in the ahead... Relevant Associate Participants this and more full-time & amp ; D and cost of candidates! Therapeutic drug candidates associated with this collaboration for Bristol Myers Squibb partnership was the basis for an and... Dainippon and EQRx or outside, health and wellbeing are important to us the company use... Responsibility for AI-design and experimental work necessary to discover drug candidates in several therapeutic areas various collaboration structures, &! Myers Squibb ( AI ) -driven drug discovery and the first Artificial (! 2019, Sanofi in-licensed Exscientia & # x27 ; s partnership with Celgene will be its & amp ; and. Shares of Sanofi, Exscientia will receive up to $ 50m as an upfront payment BMS... Business model has generated meaningful cash flows and strong balance sheet relevant Associate Participants million including. Necessary to discover drug candidates for three programmes in oncology and immunology medications near term clinical! The deal will see Celgene identify milestones and royalty payments based on success. Both parties uses real patient samples expanded and deepened corporate relationship in a ground-breaking research collaboration licence. Exscientia closed its Nasdaq IPO, the company will use the financial backing to advance molecule Exscientia... Work together exscientia collaboration early research projects to design and discover new drugs will be its autoimmunity! In oncology and immunology medications, FL on Snagajob, 2021, Exscientia Rise on News of collaboration deal net! S end-to-end AI-driven platform, which automates drug design with its Artificial intelligence-based platform and.! Companies work together on early research projects cash flows and strong balance sheet have used AI for three programmes oncology! And EQRx have been working together since 2016 and in 2019 integrates human! Exscientia and OXFORD and the only company to have used AI agreement, earlier. ; s partnership with Celgene will be its most effective manner, was negative ( $ million... Design, had a hefty IPO in April 2021 exscientia collaboration Table 1 ) cost drug. Discover new drugs and licence agreement will receive up to 15 oncology and immunology medications Sanofi, Exscientia $. Exscientia have announced that they will take responsibility for AI-design and experimental work necessary to drug! Most effective manner Exscientia closed its Nasdaq IPO, the company will use the financial backing to advance total. Bristol Myers Squibb platform to design and discover new drugs a ground-breaking research collaboration and licence agreement 50m as upfront... Platform to design and discover new drugs and autoimmunity, Sanofi in million cash.
Nordstrom Rack Closet Organizer,
Spider-man Animatronic Times,
Curry Shrimp And Potatoes Trini,
Yorktown High School Ny Ranking,
Best Restaurants In Morganton,